We narrowed to 168 results for: Ina;

1. pAAV-EF1a-Flpo (AAV Retrograde)

   Viral Prep

   #55637-AAVrg

   Purpose

   Ready-to-use AAV Retrograde particles produced from pAAV-EF1a-Flpo (#55637). In addition to the viral particles, you will also receive purified pAAV-EF1a-Flpo plasmid DNA. EF1a-driven Flpo recombinase expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth

   Article

   Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

   Promoter

   EF1a

   Tags

   None

   Available since

   April 2, 2019

   Availability

   Academic Institutions and Nonprofits only

2. pAAV-EF1a-mCherry-IRES-Flpo (AAV1)

   Viral Prep

   #55634-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pAAV-EF1a-mCherry-IRES-Flpo (#55634). In addition to the viral particles, you will also receive purified pAAV-EF1a-mCherry-IRES-Flpo plasmid DNA. EF1a-driven mCherry and bicistronic Flp recombinase expression. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth

   Article

   Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

   Promoter

   EF1a and Ef1a/IRES

   Tags

   mCherry

   Available since

   May 31, 2019

   Availability

   Academic Institutions and Nonprofits only

3. pAAV-Ef1a-Con/Foff 2.0-BFP (AAV8)

   Viral Prep

   #137130-AAV8

   Purpose

   Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-BFP (#137130). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-BFP plasmid DNA. EF1a-driven, Cre-dependent expression of BFP (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

   Depositor

   INTRSECT 2.0 Project, Karl Deisseroth

   Article

   Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

   Promoter

   EF1a

   Tags

   BFP (Cre-dependent)

   Available since

   March 19, 2021

   Availability

   Academic Institutions and Nonprofits only

4. pAAV-nEF-Con/Foff 2.0-ChR2-EYFP (AAV8)

   Viral Prep

   #137163-AAV8

   Purpose

   Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChR2-EYFP (#137163). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChR2-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of ChR2-EYFP for optogenetic activation (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

   Depositor

   INTRSECT 2.0 Project, Karl Deisseroth

   Article

   Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

   Promoter

   nEF

   Tags

   EYFP (Cre-dependent)

   Available since

   Nov. 23, 2020

   Availability

   Academic Institutions and Nonprofits only

5. pAAV-nEF-Con/Foff 2.0-ChR2-mCherry (AAV8)

   Viral Prep

   #137143-AAV8

   Purpose

   Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChR2-mCherry (#137143). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChR2-mCherry plasmid DNA. nEF-driven, Cre-dependent expression of ChR2-mCherry for optogenetic activation (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

   Depositor

   INTRSECT 2.0 Project, Karl Deisseroth

   Article

   Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

   Promoter

   nEF

   Tags

   mCherry (Cre-dependent)

   Available since

   Feb. 25, 2021

   Availability

   Academic Institutions and Nonprofits only

6. pAAV-CaMKIIa-ChRmine-oScarlet-KV 2.1-WPRE (AAV8)

   Viral Prep

   #183519-AAV8

   Purpose

   Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-ChRmine-oScarlet-KV 2.1-WPRE (#183519). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-ChRmine-oScarlet-KV 2.1-WPRE plasmid DNA. CaMKIIa-driven expression of ChRmine-oScarlet-KV 2.1. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth

   Article

   Kishi et al Cell. 2022 Feb 17;185(4):672-689.e23. do

   Promoter

   CaMKII

   Tags

   None

   Available since

   Dec. 18, 2024

   Availability

   Academic Institutions and Nonprofits only

7. pGP-AAV-syn-FLEX-jGCaMP7c variant 1513-WPRE (AAV1)

   Viral Prep

   #105322-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pGP-AAV-syn-FLEX-jGCaMP7c variant 1513-WPRE (#105322). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-jGCaMP7c variant 1513-WPRE plasmid DNA. Synapsin-driven, Cre-dependent jGCaMP7c expression. jGCaMP7c exhibits high contrast between peak fluorescence and resting fluorescence. It is useful for activity imaging of large populations of densely-labeled neurons because background fluorescence from inactive neurons is reduced. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Douglas Kim, GENIE Project

   Article

   Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

   Promoter

   Syn

   Tags

   None

   Available since

   June 13, 2019

   Availability

   Academic Institutions and Nonprofits only

8. pGP-AAV-syn-jGCaMP7c variant 1513-WPRE (AAV1)

   Viral Prep

   #105321-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pGP-AAV-syn-jGCaMP7c variant 1513-WPRE (#105321). In addition to the viral particles, you will also receive purified pGP-AAV-syn-jGCaMP7c variant 1513-WPRE plasmid DNA. Synapsin-driven jGCaMP7c expression. jGCaMP7c exhibits high contrast between peak fluorescence and resting fluorescence. It is useful for activity imaging of large populations of densely-labeled neurons because background fluorescence from inactive neurons is reduced. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Douglas Kim, GENIE Project

   Article

   Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

   Promoter

   Syn

   Tags

   None

   Available since

   July 12, 2019

   Availability

   Academic Institutions and Nonprofits only